Skip to main content

Table 2 Lipid parameters before and after administration of dapagliflozin or sitagliptin

From: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin

  Dapagliflozin (n = 40) Sitagliptin (n = 40) p valueb
Pre treatment Post treatment % change p valuea Pre treatment Post treatment % change p valuea
Total-C (mg/dL) 193.5 ± 36.6 198.4 ± 45.9 2.5 0.863 192.5 ± 58.2 195.5 ± 38.9 1.6 0.720 0.102
TG (mg/dL) 152.6 ± 63.7 133.7 ± 75.8 −12.4 0.145 150.2 ± 85.2 144.6 ± 87.2 −3.7 0.245 0.928
HDL-C (mg/dL) 48.4 ± 11.1 53.5 ± 13.0 10.5 <0.001* 50.3 ± 9.25 50.3 ± 11.1 0 0.948 0.003*
LDL-C (mg/dL) 118.2 ± 32.1 118.8 ± 39.7 0.5 0.875 120.2 ± 35.1 114.7 ± 33.1 −4.6 0.257 0.323
Non HDL-C (mg/dL) 145.1 ± 36.0 144.9 ± 439 −0.1 0.947 142.2 ± 57.3 145.1 ± 38.4 2.9 0.717 0.328
Apo AI (mg/dL) 133.5 ± 21.6 143.5 ± 22.6 7.5 0.002* 134.9 ± 25.2 128.8 ± 30.7 −4.5 0.135 0.002*
Apo AII (mg/dL) 29.7 ± 4.5 30.9 ± 5.0 4.0 0.022* 30.5 ± 7.2 30.5 ± 7.2 0 0.945 0.148
Apo B (mg/dL) 100.1 ± 24.5 100.8 ± 28.1 0.7 0.777 102.3 ± 27.7 97.4 ± 26.5 −4.8 0.123 0.131
Apo CII (mg/dL) 4.8 ± 1.7 4.9 ± 2.2 2.1 0.362 5.4 ± 2.8 5.1 ± 2.6 −5.6 0.197 0.105
Apo CIII (mg/dL) 10.5 ± 3.2 11.4 ± 4.3 8.6 0.021* 10.1 ± 4.5 9.6 ± 4.0 −5.0 0.335 0.028*
Apo E (mg/dL) 4.4 ± 1.2 4.4 ± 1.5 0 0.530 4.3 ± 1.5 4.1 ± 1.0 −4.7 0.296 0.216
RLP-C (mg/dL) 6.8 ± 4.3 6.4 ± 5.1 −5.9 0.620 6.9 ± 8.0 6.1 ± 5.7 −11.6 0.303 0.750
HDL2-C (mg/dL) 26.1 ± 8.2 30.8 ± 10.8 18.0 <0.001* 26.6 ± 7.9 27.5 ± 8.4 3.4 0.334 0.013*
HDL3-C (mg/dL) 22.2 ± 3.9 22.7 ± 5.0 2.3 0.527 23.3 ± 5.2 22.2 ± 5.3 −4.7 0.132 0.130
sd LDL-C (mg/dL) 54.4 ± 24.6 43.6 ± 24.4 −19.9 0.005* 54.0 ± 22.5 50.4 ± 22.4 −6.7 0.368 0.003*
lb LDL-C (mg/dL) 63.8 ± 27.6 75.1 ± 34.1 17.7 0.026* 66.2 ± 26.3 64.3 ± 24.1 −2.9 0.671 0.029*
  1. Data are expressed as mean ± standard deviation or percent changes after the treatment
  2. Total-C total-cholesterol, TG triglycerides, HDL-C high-density lipoprotein-cholesterol, LDL-C low-density lipoprotein-cholesterol, Apo apolipoprotein, RLP-C remant-like particles-cholesterol, sd LDL-C small dense LDL-cholesterol, lb LDL-C large buoyant LDL-cholesterol, HDL2-C high-density lipoprotein 2-cholesterol, HDL3-C high-density lipoprotein 3-cholesterol
  3. ap values for the intragroup comparison (pre vs. post treatment values in dapagliflozin or sitagliptin group, * p < 0.05)
  4. bp values for intergroup comparison (dapagliflozin vs. sitagliptin group in the changes from pre to post treatment, * p < 0.05)